1. Home
  2. IMCR vs DAC Comparison

IMCR vs DAC Comparison

Compare IMCR & DAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Immunocore Holdings plc

IMCR

Immunocore Holdings plc

HOLD

Current Price

$34.82

Market Cap

1.8B

Sector

Health Care

ML Signal

HOLD

Logo Danaos Corporation

DAC

Danaos Corporation

HOLD

Current Price

$94.08

Market Cap

1.7B

ML Signal

HOLD

Company Overview

Basic Information
Metric
IMCR
DAC
Founded
2008
1972
Country
United Kingdom
Greece
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Marine Transportation
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2021
2006

Fundamental Metrics

Financial Performance
Metric
IMCR
DAC
Price
$34.82
$94.08
Analyst Decision
Buy
Strong Buy
Analyst Count
9
1
Target Price
$67.00
$105.00
AVG Volume (30 Days)
269.1K
68.7K
Earning Date
11-06-2025
02-09-2026
Dividend Yield
N/A
3.79%
EPS Growth
N/A
N/A
EPS
N/A
25.05
Revenue
$379,590,000.00
$1,034,370,000.00
Revenue This Year
$32.28
N/A
Revenue Next Year
$10.66
$1.29
P/E Ratio
N/A
$3.79
Revenue Growth
28.11
2.90
52 Week Low
$23.15
$65.40
52 Week High
$40.72
$100.00

Technical Indicators

Market Signals
Indicator
IMCR
DAC
Relative Strength Index (RSI) 40.33 48.48
Support Level $35.41 $93.65
Resistance Level $36.64 $95.47
Average True Range (ATR) 1.51 1.66
MACD -0.25 -0.16
Stochastic Oscillator 3.99 52.45

Price Performance

Historical Comparison
IMCR
DAC

About IMCR Immunocore Holdings plc

Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.

About DAC Danaos Corporation

Danaos Corp is an international owner of containerships. It provides international seaborne transportation services by operating vessels in the containership sector of the shipping industry. The company's customers include, HMM, MSC, Yang Ming, Hapag Lloyd, ZIM, Maersk, COSCO, OOCL, ONE, PIL, Sealead, Niledutch, Samudera, OSC, and Arkas. Geographically, the company operates in Australia-Asia, Europe, and America, with maximum revenue from the Australia-Asia region. It has two reporting segments Container vessels and Drybulk vessels segment. It generates the majority of its revenue from Container vessels.

Share on Social Networks: